Apogee Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $APGE in the last 7 days.
AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.
Fairmount Funds Management sold its entire 298,647-share stake in Apogee Therapeutics (APGE) at $135.09 per share, reducing its portfolio value by 2.62%. Apogee's stock has surged 541.66% since its 2023 IPO and 78.24% year-to-date, despite being unprofitable. The company focuses on inflammatory and immunology therapies.
Apogee Therapeutics (APGE) is being acquired by AbbVie (ABBV) in a $135.11-per-share cash deal. The merger closed on September 3, 2026, with Apogee's stock ceasing to trade on Nasdaq the following day. Shareholders received $135.11 per share, and Apogee became a wholly owned subsidiary of AbbVie.
Recent APGE coverage spans insider activity, mergers & acquisitions and financial news.
In the last 30 days, APGE insiders filed 11 SEC Form 4 transactions — no purchases and 11 sales ($236.6M). The most active reporter was Fairmount Funds Management LLC with 3 filings.
Shareholders receive cash premium; the company’s pipeline now under AbbVie’s commercial engine.
The fund's full exit may signal valuation concerns and could trigger short‑term selling pressure.
Shares are cancelled and cash paid; stock delists, providing a definitive exit for shareholders.
The deregistration removes any remaining unissued shares from the market, eliminating potential future dilution but has no immediate cash impact.
The cash-out of options signals the merger consideration and may affect APGE share perception.
AlphAI scores every news story that mentions APGE with an AI model for sentiment and relevance, and aggregates insider trades from Apogee Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.
3 min readFairmount Funds Management sold its entire 298,647-share stake in Apogee Therapeutics (APGE) at $135.09 per share, reducing its portfolio value by 2.62%. Apogee's stock has surged 541.66% since its 2023 IPO and 78.24% year-to-date, despite being unprofitable. The company focuses on inflammatory and immunology therapies.
1 min readApogee Therapeutics (APGE) is being acquired by AbbVie (ABBV) in a $135.11-per-share cash deal. The merger closed on September 3, 2026, with Apogee's stock ceasing to trade on Nasdaq the following day. Shareholders received $135.11 per share, and Apogee became a wholly owned subsidiary of AbbVie.
2 min readApogee Therapeutics (APGE), now a subsidiary of AbbVie, has deregistered unsold securities worth up to $300M following its merger with Andor Merger Co. The merger, completed on September 3, 2026, terminated all offerings under the registration statement.
1 min readApogee Therapeutics (APGE) director Lisa Bollinger cashed out vested stock options in a merger deal with AbbVie. The options, covering 48,780 shares, were canceled and exchanged for $135.11 per share minus exercise prices ranging from $41.66 to $85.00. The transaction occurred on September 3, 2026, under a merger agreement dated June 18, 2026.
1 min readMcKenna Mark C. sold (to issuer) 20,000 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.
1 min readJONES WILLIAM A JR sold (to issuer) 34,824 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.
1 min readDambkowski Carl (Chief Medical Officer) sold (to issuer) 168,498 shares of Apogee Therapeutics, Inc. (APGE) at $135.06 ($0.19M total) across 2 trades over 2026-09-02 to 2026-09-03.
1 min readFox Jennifer A. sold (to issuer) 34,824 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.
1 min readHenderson Jane (Chief Financial Officer) sold (to issuer) 158,371 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.
1 min read
